HCA Healthcare Inc. (HCA)
HCA Healthcare's Warning Prices In All The Bad News (Upgrade)
HCA Healthcare is upgraded to "Buy" after recent underperformance, with shares now reflecting payer mix and policy headwinds. HCA's Q2 results beat expectations due to a $400 million one-time Medicaid payment, masking underlying margin compression from a worsening payer mix. Guidance was cut, with 2026 EPS now seen at $29–$30 (excluding windfall: ~$28), and free cash flow run-rate at ~$6 billion, reflecting persistent policy pressures.
HCA Healthcare Stock Falls as Uninsured Patients and Declining Surgeries Dent Outlook
HCA Healthcare stock falls after the hospital chain operator lowers its full-year profit outlook as uninsured patients rise in the second quarter.
HCA Healthcare Shares Drop After Quarterly Earnings Squeezed by Payer Mix Shifts
The for-profit operator of healthcare facilities scaled back financial guidance for the year following payer mix shifts due to health insurance exchanges.
HCA reports preliminary quarterly revenue above expectations
HCA Healthcare on Tuesday reported preliminary second-quarter revenue above Wall Street expectations.
Is the Options Market Predicting a Spike in HCA Healthcare Stock?
Investors need to pay close attention to HCA stock based on the movements in the options market lately.
HCA Healthcare's Fall Shouldn't Be Construed As Failing Health
HCA Healthcare remains a soft 'buy' despite recent underperformance, with fundamentals improving and shares attractively priced on an absolute basis. HCA's revenue and profitability continue to grow, driven by Medicare/Medicaid, increased equivalent admissions, and higher revenue per admission, even as the physical footprint shrinks. Management sustains shareholder returns through dividends and aggressive buybacks, with a 6.9% reduction in share count and $9.18 billion in remaining buyback capacity.
Can HCA's Capacity Expansion Strategy Fuel Its Long-Term Growth?
HCA is expanding hospitals, ERs and outpatient sites while investing billions in new capacity to support future healthcare demand and long-term growth.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Can HCA's Gene Therapy Milestone Drive Long-Term Growth?
HCA Healthcare highlights promising pediatric CRISPR gene therapy results as expanding specialty care and research investments support its long-term growth strategy.
HCA Healthcare (HCA) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
